Table 5.
KRAS mutated adenocarcinomas (pancreatic metastases and primaries, and lung primaries)
| (1) Metastatic PDAC KRAS + (n =23a) | (2) Primary PDAC KRAS + (n =94) | (3) Primary lung KRAS + (n =284) | P-value | |
|---|---|---|---|---|
| Sex (M/F) | 13/10 | 53/42 | 117/167 | 0.032 (2 vs 3) |
| Age (mean), years | 63 (range, 48–77) | 67 (range, 32–88) | 66 (range, 39–92) | NS |
| KRAS mutations (amino acid/nucleotide) | ||||
| Transition mutations | ||||
| G12D/GGT→GAT | 9 | 50 | 45 | 0.009 (1 vs 3), 0.0001 (2 vs 3) |
| G12S/GGT→AGT | 0 | 0 | 9 | NS |
| Total | 9 | 50 | 54 | <0.0001 (2 vs 3)b |
| Transversion mutations | ||||
| G12V/GGT→GTT | 7 | 27 | 53 | NS (1 vs 3), 0.042 (2 vs 3) |
| G12R/GGT→CGT | 5 | 13 | 3 | 0.0001 (1 or 2 vs 3) |
| G12C/GGT→TGT | 2 | 3 | 125 | 0.0007 (1 vs 3), 0.0001 (2 vs 3) |
| G12A/GGT→GCT | 0 | 1 | 22 | NS (1 vs 3),0.022 (2 vs 3) |
| G12F/GGT→TTT | 0 | 0 | 7 | NS |
| G12L/GGT→CTT | 0 | 0 | 1 | NS |
| Total | 14 | 44 | 211 | <0.0001 (2 vs 3)b |
| Codon 13 mutations | ||||
| G13x | 0 | 0 | 19 | NS |
Abbreviations: AA, amino acid; NS, not significant; PDAC, pancreatic ductal adenocarcinoma; x is either D, C, or V.
a
A total of 24 metastatic PDAC harbored KRAS mutations, but the specific mutation was unknown in one case, so this case was excluded from this table.
b
P<0.0001 for transition versus transversion mutations in primary pancreatic versus primary lung adenocarcinomas.